S0847 Pregnancy Outcomes in the Tofacitinib Ulcerative Colitis OCTAVE Studies: An Update as of February 2020
Bibliographic record
Abstract
INTRODUCTION: Pregnant women with UC have a higher risk of adverse pregnancy outcomes compared with age-matched controls [1]. Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. In rats and rabbits, tofacitinib exhibits teratogenic effects at 146 and 13 times, respectively, the human dose of 5 mg twice daily. There are no adequately sized, well-controlled studies of tofacitinib in pregnant women. METHODS: We report updated pregnancy outcomes [2] from 3 randomized, placebo-controlled studies (OCTAVE Induction 1&2: NCT01465763, NCT01458951; OCTAVE Sustain: NCT01458574) and an ongoing, open-label, long-term extension study (OCTAVE Open: NCT01470612) of tofacitinib in patients (pts) with moderately to severely active UC [3,4]. Pregnancy outcomes following maternal or paternal exposure to tofacitinib were identified from Pfizer’s internal safety database up to Feb 11, 2020, and categorized as healthy newborn, medical termination, fetal death, congenital malformation, spontaneous abortion, or lost to follow-up. Trial protocols required females of childbearing potential to use highly effective contraception, and included regular urine β-hCG testing. The study drug was discontinued in pts who became pregnant. RESULTS: The UC OCTAVE trials included 1,139 unique pts (including placebo), of whom 296 were females of childbearing age. A total of 34 pregnancies with exposure to tofacitinib were reported. Of these, 15 were cases of maternal exposure, all during the 1st trimester: 9 (60.0%) healthy newborns, 2 (13.3%) medical terminations, 2 (13.3%) spontaneous abortions, and 2 (13.3%) cases lost to follow-up. There were 19 cases of paternal exposure: 15 (78.9%) healthy newborns, 2 (10.5%) spontaneous abortions, and 2 (10.5%) cases lost to follow-up. There were no cases of fetal death or congenital malformation. CONCLUSION: The majority of known outcomes for both maternal and paternal cases were healthy newborns. Although there are limited data and follow-up available, this analysis was consistent with a previous analysis in pts with UC [2], as well as an analysis in pts with rheumatoid arthritis and psoriasis [5]. Tofacitinib should not be used during pregnancy unless clearly necessary.Table 1
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".